Want to see SLP full AI Analyst Report?
SLP Stock Chart & Stats
$11.43
-$4.39(-14.45%)
At close: 4:00 PM EST
$11.43
-$4.39(-14.45%)
Day’s Range― - ―
52-Week Range$11.09 - $21.01
Previous CloseN/A
Volume738.72K
Average Volume (3M)527.53K
Market Cap
$368.70M
Enterprise Value$296.79
Total Cash (Recent Filing)$49.99M
Total Debt (Recent Filing)$487.00K
Price to Earnings (P/E)44.5
Beta1.45
Next Earnings
Oct 28, 2026EPS Estimate
0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.41
Shares Outstanding20,224,838
10 Day Avg. Volume350,868
30 Day Avg. Volume527,531
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.28
Price to Sales (P/S)3.60
P/FCF Ratio16.36
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$17.25Price Target Upside50.92% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)0.87
Revenue Forecast (FY)$81.71M
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation And Conservative Balance SheetRobust operating cash flow and near-parity free cash flow show durable internal funding for R&D, product development and services. Extremely low leverage and a $41.8M cash position provide flexibility to invest, withstand downturns, or pursue strategic M&A without financing strain.
Very High Software Gross Margins And Recurring MixExceptional software gross margins reflect scalable, high‑value licensing and support economics that sustain profitability as subscriptions grow. A majority recurring software mix reduces cost-per-revenue and supports durable margin expansion even if services ebb, underpinning long-term cash generation.
Growing Services Backlog And Meaningful Cross-sell PotentialAn increasing services backlog signals repeatable, contracted demand and predictable near-term revenue. Combined with a broad client base and demonstrated cross-sell (multiple-product adoption among larger customers), this supports stickiness, higher lifetime value and durable revenue diversification.
Bears Say
Softening Renewal Rates And Concentrated ChurnDeclining renewals and concentration of churn in smaller or precommercial customers weaken the predictability of recurring revenue. Persistent lower renewal trends increase sales and retention investment needs and make revenue growth more sensitive to biotech funding cycles and client program timing.
Material Earnings Volatility, Including FY2025 Net LossA large prior-year net loss and negative ROE highlight operational or one-time swings that undermine earnings consistency. Such volatility complicates resource allocation, forecasting and the credibility of profit trends, making sustainable EPS improvement and return metrics less certain over the medium term.
Limited Near-term AI Monetization And Conservative GuidanceWhile strategic AI partnerships are promising, delayed monetization means anticipated long-term upside may not aid near-term revenue or margins. Conservative guidance signals management caution and limits visibility into when AI-driven revenue acceleration or subscription transformation will materially affect core fundamentals.
Simulations Plus News
SLP FAQ
What was Simulations Plus’s price range in the past 12 months?
Simulations Plus lowest stock price was $11.09 and its highest was $21.01 in the past 12 months.
What is Simulations Plus’s market cap?
Simulations Plus’s market cap is $368.70M.
When is Simulations Plus’s upcoming earnings report date?
Simulations Plus’s upcoming earnings report date is Oct 28, 2026 which is in 101 days.
How were Simulations Plus’s earnings last quarter?
Simulations Plus released its earnings results on Jul 09, 2026. The company reported $0.3 earnings per share for the quarter, beating the consensus estimate of $0.232 by $0.068.
Is Simulations Plus overvalued?
According to Wall Street analysts Simulations Plus’s price is currently Undervalued.
Does Simulations Plus pay dividends?
Simulations Plus pays a Quarterly dividend of $0.06 which represents an annual dividend yield of N/A. See more information on Simulations Plus dividends here
What is Simulations Plus’s EPS estimate?
Simulations Plus’s EPS estimate is 0.13.
How many shares outstanding does Simulations Plus have?
Simulations Plus has 20,224,838 shares outstanding.
What happened to Simulations Plus’s price movement after its last earnings report?
Simulations Plus reported an EPS of $0.3 in its last earnings report, beating expectations of $0.232. Following the earnings report the stock price went down -0.545%.
Which hedge fund is a major shareholder of Simulations Plus?
Currently, no hedge funds are holding shares in SLP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Simulations Plus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$17.25 (50.92% Upside)
$17.25 (50.92% Upside)
Blogger Sentiment
Neutral
SLP Sentiment 50%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 309.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.2%
Last 30 Days <0.1%
Last 30 Days <0.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
42.53%
12-Months-Change
Fundamentals
Return on Equity
-49.30%
Trailing 12-Months
Asset Growth
13.86%
Trailing 12-Months
Company Description
Simulations Plus
Simulations Plus, Inc. (SLP) is a worldwide developer of sophisticated software and services aimed at enhancing drug discovery and development processes. The company employs artificial intelligence and machine learning technologies to create tools for modeling, simulation, and predicting molecular characteristics. Its operations are divided into four main business units: Simulations Plus, Cognigen, DILIsym, and Lixoft. Among its diverse software offerings are GastroPlus, which models the absorption and drug interactions of compounds in both human and animal subjects, as well as DDDPlus and MembranePlus for various simulations. The company also provides a range of products built on mechanistic and mathematical models, such as its quantitative systems pharmacology software like DILIsym, NAFLDsym, IPFsym, RENAsym, and MITOsym. Furthermore, Simulations Plus offers the ADMET Predictor, a chemistry-focused computer program that forecasts molecular properties from structural inputs, alongside MedChem Designer, MonolixSuite, and PKPlus for additional modeling and simulation needs. Beyond software, the company extends its expertise through various services, including contract research for population modeling and simulation, specialized training and consultation to advance pharmacometrics studies, and clinical-pharmacology consulting to aid in regulatory submissions. Simulations Plus serves a broad spectrum of clients globally, including pharmaceutical, biotechnology, agrochemical, cosmetic, and food companies, as well as academic institutions and regulatory bodies. The company was founded in 1996 and maintains its headquarters in Lancaster, California.
SLP Stock 12 Month Forecast
Average Price Target
$17.25
▲(50.92% Upside)
Technical Analysis
Ownership Overview
16.94% Insiders
14.80% Mutual Funds
1.06% Other Institutional Investors
57.15% Public Companies and
Individual Investors